Investing

Today’s 52-Week Low Club

down market
Source: Thinkstock
July 28, 2014: Stocks making new 52-week lows today include three healthcare firms and one shipping company. The lows given below were set today.

Cerulean Pharma Inc. (NASDAQ: CERU) held its initial public offering (IPO) in April and the stock’s post IPO range is $4.10 to $8.06. Shares tumbled 20% in mid-June and have been on a steady slide since then. Shares were trading down more than 10% today on no news.

Semler Scientific Inc. (NASDAQ: SMLR) held its IPO in February and its share price is down about 47% since the offering. The post-IPO range is $2.75 to $7.25. The stock was downgraded from Buy to Hold today at Aegis Capital, which initiated coverage on the share with a Buy rating about six weeks ago. Shares were down nearly 20% today.

Rock Creek Pharmaceuticals Inc. (NASDAQ: RCPI) changed its name and ticker symbol earlier this month from Star Scientific Inc. (STSI) but that has not helped the shares which have traded below $1 for most of 2014. The stock’s 52-week, range is $0.40 to $2.59. Shares traded down about more than 16% today.

NewLead Holdings Ltd. (NASDAQ: NEWL) held a 1-for-50 reverse stock split effective July 15th in an effort to boost the share price above a dollar. The shipping company had no news today, but the shares fell more than 10% to a new 52-week low of $0.66. The 52-week high is not meaningful.

ALSO READ: 5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here
you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.


Click here
to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.